Boston Life Sciences, Inc. to Present at the CIBC World Markets 17th Annual Healthcare Conference
06 November 2006 - 3:17PM
PR Newswire (US)
HOPKINTON, Mass., Nov. 6 /PRNewswire-FirstCall/ -- Boston Life
Sciences, Inc. (NASDAQ:BLSI) today announced that Ken Rice,
Executive Vice President and Chief Financial Officer of Boston Life
Sciences, Inc., will be presenting a Company update at the CIBC
World Markets 17th Annual Healthcare Conference on Tuesday,
November 7 from 11:30am - 11:50am EST. The conference is being held
from November 6 - 8 at the Waldorf-Astoria in New York City, NY.
The Boston Life Sciences presentation will be available by webcast.
Access to the webcast will be available within the Investor
Relations section of the Boston Life Sciences website at
http://www.bostonlifesciences.com/. About Boston Life Sciences,
Inc. Boston Life Sciences, Inc. (BLSI) is engaged in the research
and clinical development of diagnostic and therapeutic products for
central nervous system (CNS) disorders. ALTROPANE(R) molecular
imaging agent is in Phase III clinical trials for the diagnosis of
Parkinsonian Syndrome (PS) and Phase II clinical trials for the
diagnosis of Attention Deficit Hyperactivity Disorder (ADHD). The
Company's research and pre-clinical CNS programs include Inosine
for the treatment of stroke, a DAT blocker for the treatment of
Parkinson's disease and a second generation technetium-based
molecular imaging agent for PS and ADHD. BLSI's current research
collaborations include Harvard Medical School and Children's
Hospital Boston. Contact: Sharon Correia -- 508-497-2360 ext 224
Boston Life Sciences, Inc. DATASOURCE: Boston Life Sciences, Inc.
CONTACT: Sharon Correia of Boston Life Sciences, Inc.,
+1-508-497-2360, ext. 224, Web site:
http://www.bostonlifesciences.com/
Copyright
Boston Life Sciences (NASDAQ:BLSI)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
Boston Life Sciences (NASDAQ:BLSI)
Historical Stock Chart
Von Jun 2023 bis Jun 2024
Echtzeit-Nachrichten über Boston Life Sciences (MM) (NASDAQ): 0 Nachrichtenartikel
Weitere Boston Life Sciences (MM) News-Artikel